JPRN-UMIN000048397招募中Unknown
A multicenter prospective study to evaluate the effect of elobixibat on spontaneous defecation without a feeling of residual stool in patients with chronic constipation who are inadequately effective with magnesium oxide, a first-line treatment for constipation. - A multicenter prospective study to evaluate the effect of elobixibat on spontaneous defecation without a feeling of residual stool in patients with chronic constipation who are inadequately effective with magnesium oxide, a first-line treatment for constipation.
Medical corporation Irisawa Medical Clinic0 个研究点目标入组 26 人开始时间: 2022年7月18日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 120years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with a history of hypersensitivity to elobixibat 2) Patients with confirmed or suspected intestinal obstruction due to tumor, hernia, etc. 3) Patients suspected of having constipation due to organic disease 4) Patients taking other laxatives 5) Others who are judged by the principal investigator to be inappropriate as research subjects
研究者
相似试验
已完成
不适用
arge cell D-type stents for patients with inoperable malignant hilar biliary obstructioNeoplasmsKCT0002198Ajou University Hospital40
已完成
不适用
Prospective multicenter Study to evaluate the Effect of tight and systematic monitoring by Ultrasound on Therapy and Outcome in Patients with early rheumatoid ArthritisM05Seropositive rheumatoid arthritisrheumatoid arthritisDRKS00010485Charité Universitätsmedizin Berlin -Med. Klinik mit SP Rheumatologie und Klin. Immunologie453
尚未招募
不适用
Multicenter randamized study for evaluating the effect of dantrolene aganst heart failure and arrhythmiaheart failureJPRN-UMIN000022756Yamaguchi University Graduate School of Medicine100
进行中（未招募）
不适用
A multi-centre randomised study to evaluate the efficacy of Betaferon-interferon-beta-1b (IFNB-1B) 500 mcg therapy in the induction of tolerance to IFNB in MS patients with neutralising antibodies (NAbs) to IFNB-1a (Rebif) - Betaferon NaB Anergy StudyMultiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system of unknown aetiology. It is the commonest cause of disability in young adults. The prevalence in the UK is approximately 125/100,000 of the population with an annual incidence of 6/100,000. Approximately 80,000 individuals are affected with MS in the UK.EUCTR2005-005751-18-GBCL Biomedicine R&D Unit100
尚未招募
不适用
A Prospective randomized multi-center study for efficacy of metallic biliary stent compared to plastic stent in patients receiving neoadjuvant chemotherapy for resectable pancreatic cancerKCT0006294Yonsei University Health System, Severance Hospital196